Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-03 · accession 0000950170-25-003153 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-07 | 2025-01-03 | ANTX | Prior Stephen David | Chief Strategy Off | S - Sale | $1.34 | -2,029 | 33.3K | -6% | -$2,719 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-03 | S | D | 2,029 | $1.34 | 33,313 | D | — | — | (F1) Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025. (F2) Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. |